AMPH – Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals, Inc.AMPH
$27.62Name : Amphastar Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $1,284,194,176.00
EPSttm : 2.26
Amphastar Pharmaceuticals, Inc.
$27.62
3.37%$0.9Float Short %
11.98
Margin Of Safety %
18
Put/Call OI Ratio
0.23
EPS Next Q Diff
-0.04
EPS Last/This Y
0.09
EPS This/Next Y
0.2
Price
27.61
Target Price
31.71
Analyst Recom
2.14
Performance Q
3.91
Relative Volume
0.74
Beta
0.87
Ticker: AMPH
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-08 | AMPH | 26 | 0.29 | 1.82 | 1067 |
| 2025-12-09 | AMPH | 25.64 | 0.29 | 0.00 | 1066 |
| 2025-12-10 | AMPH | 25.71 | 0.29 | 999.99 | 1067 |
| 2025-12-11 | AMPH | 25.88 | 0.32 | 1.25 | 1087 |
| 2025-12-12 | AMPH | 25.27 | 0.32 | 999.99 | 1094 |
| 2025-12-15 | AMPH | 26.33 | 0.30 | 0.46 | 1076 |
| 2025-12-16 | AMPH | 25.63 | 0.30 | 0.00 | 1080 |
| 2025-12-17 | AMPH | 26.08 | 0.28 | 0.03 | 1123 |
| 2025-12-18 | AMPH | 26.51 | 0.25 | 0.05 | 1237 |
| 2025-12-19 | AMPH | 26.58 | 0.26 | 0.02 | 1294 |
| 2025-12-22 | AMPH | 27.33 | 0.24 | 1.40 | 540 |
| 2025-12-23 | AMPH | 26.46 | 0.24 | 0.00 | 546 |
| 2025-12-26 | AMPH | 27.13 | 0.24 | 0.00 | 549 |
| 2025-12-29 | AMPH | 26.81 | 0.24 | 0.05 | 554 |
| 2025-12-30 | AMPH | 27.03 | 0.23 | 0.00 | 575 |
| 2025-12-31 | AMPH | 26.78 | 0.23 | 0.00 | 579 |
| 2026-01-02 | AMPH | 26.47 | 0.23 | 0.00 | 580 |
| 2026-01-05 | AMPH | 26.73 | 0.23 | 0.00 | 581 |
| 2026-01-06 | AMPH | 27.64 | 0.23 | 0.00 | 581 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-08 | AMPH | 26.01 | 0.2 | - | 3.35 |
| 2025-12-09 | AMPH | 25.65 | 0.2 | - | 3.35 |
| 2025-12-10 | AMPH | 25.65 | 0.2 | - | 3.35 |
| 2025-12-11 | AMPH | 25.90 | 0.2 | - | 3.36 |
| 2025-12-12 | AMPH | 25.26 | 0.6 | - | 3.36 |
| 2025-12-15 | AMPH | 26.31 | 0.6 | - | 3.36 |
| 2025-12-16 | AMPH | 26.31 | 0.6 | - | 3.36 |
| 2025-12-17 | AMPH | 26.08 | 0.6 | - | 3.36 |
| 2025-12-18 | AMPH | 26.51 | 0.6 | - | 3.38 |
| 2025-12-19 | AMPH | 26.59 | 0.2 | - | 3.38 |
| 2025-12-22 | AMPH | 27.28 | 0.2 | - | 3.38 |
| 2025-12-23 | AMPH | 26.47 | 0.2 | - | 3.38 |
| 2025-12-26 | AMPH | 27.14 | 0.2 | - | 3.38 |
| 2025-12-29 | AMPH | 26.78 | 0.2 | - | 3.38 |
| 2025-12-30 | AMPH | 27.02 | 0.2 | - | 3.38 |
| 2025-12-31 | AMPH | 26.81 | 0.2 | - | 3.38 |
| 2026-01-02 | AMPH | 26.48 | 0.2 | - | 3.38 |
| 2026-01-05 | AMPH | 26.74 | 0.2 | - | 3.38 |
| 2026-01-06 | AMPH | 27.61 | 0.2 | - | 3.38 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-08 | AMPH | -0.19 | 0.26 | 10.74 |
| 2025-12-09 | AMPH | -0.19 | 0.26 | 10.74 |
| 2025-12-10 | AMPH | -0.19 | 0.26 | 10.00 |
| 2025-12-11 | AMPH | -0.19 | 0.26 | 10.00 |
| 2025-12-12 | AMPH | -0.19 | 0.26 | 10.00 |
| 2025-12-15 | AMPH | -0.19 | 0.08 | 10.05 |
| 2025-12-16 | AMPH | -0.22 | 0.08 | 10.05 |
| 2025-12-17 | AMPH | -0.22 | 0.08 | 10.05 |
| 2025-12-18 | AMPH | -0.22 | 0.08 | 10.05 |
| 2025-12-19 | AMPH | -0.29 | 0.08 | 10.05 |
| 2025-12-22 | AMPH | -0.29 | 0.01 | 10.05 |
| 2025-12-23 | AMPH | -0.29 | 0.01 | 10.06 |
| 2025-12-26 | AMPH | -0.29 | 0.01 | 11.98 |
| 2025-12-29 | AMPH | -0.29 | -0.01 | 11.98 |
| 2025-12-30 | AMPH | -0.29 | -0.01 | 11.98 |
| 2025-12-31 | AMPH | -0.29 | -0.01 | 11.98 |
| 2026-01-02 | AMPH | -0.29 | -0.01 | 11.98 |
| 2026-01-05 | AMPH | -0.29 | -0.01 | 11.98 |
| 2026-01-06 | AMPH | -0.29 | -0.01 | 11.98 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.83
Avg. EPS Est. Current Quarter
0.92
Avg. EPS Est. Next Quarter
0.79
Insider Transactions
-0.29
Institutional Transactions
-0.01
Beta
0.87
Average Sales Estimate Current Quarter
190
Average Sales Estimate Next Quarter
169
Fair Value
32.71
Quality Score
83
Growth Score
87
Sentiment Score
2
Actual DrawDown %
59.2
Max Drawdown 5-Year %
-68.3
Target Price
31.71
P/E
12.25
Forward P/E
7.55
PEG
P/S
1.75
P/B
1.65
P/Free Cash Flow
11.21
EPS
2.26
Average EPS Est. Cur. Y
3.38
EPS Next Y. (Est.)
3.58
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
15.43
Relative Volume
0.74
Return on Equity vs Sector %
-12.7
Return on Equity vs Industry %
7.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.03
EBIT Estimation
Amphastar Pharmaceuticals, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 2028
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
stock quote shares AMPH – Amphastar Pharmaceuticals Inc Stock Price stock today
news today AMPH – Amphastar Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch AMPH – Amphastar Pharmaceuticals Inc yahoo finance google finance
stock history AMPH – Amphastar Pharmaceuticals Inc invest stock market
stock prices AMPH premarket after hours
ticker AMPH fair value insiders trading